SomaLogic, Inc., a global leader in proteomics technology, has announced tis first grant in the APAC region by sponsoring the Genomax Research Grant Award for researchers in Singapore.

The winners of the award will receive proteomic data from SomaLogic’s 7,000-plex assay, which will be run at Singapore-based Molecular Genomics, a Genomax Technologies company.

The Genomax site, opened in November 2022, was the first SomaLogic authorized site in Asia to offer the SomaScan® Platform. The grant program, which was launched at the Asia Oceana Human Proteome Organisation (AOHUPO) meeting in Singapore, requires that researchers in academic, medical centers, pharmaceutical companies, and contract research organizations in life sciences, submit a proposal outlining how they will use the SomaScan Platform to expand their research goals in health or in a specific disease area.

Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan Platform at Genomax’s Singapore lab.

Researchers can apply on SomaLogic’s website: http://somalogic.com/genomaxgrant2023.

While experts across the region have long embraced the value of genomics, life science researchers in Asia are now increasingly appreciating the power and the promise of proteomics in their discovery efforts. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.

SomaLogic Chief Executive Officer Adam Taich shared, “inaugural grant program encourages researchers in Singapore to advance their studies through our partnership with Molecular Genomics, which has been accelerating biodiscovery in Southeast Asia for more than a decade.